PentaBind uses Generative AI and aptamers for innovative drug discovery and diagnostics in biotechnology.
PentaBind has raised $845K in total funding. The most recent round was Pre-Seed. The last funding was announced in January 2024.
PentaBind's investors include Entrepreneurs First, Twin Path Ventures.
PentaBind is headquartered in London, United Kingdom.
PentaBind uses Generative AI and aptamers for innovative drug discovery and diagnostics in biotechnology.
PentaBind is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PentaBind — Funding & Investors." VCBacked, January 11, 2024, https://www.vcbacked.co/company/pentabind. Accessed August 14, 2026.
VCBacked. (2024). PentaBind — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/pentabind
{{cite web |title=PentaBind — Funding & Investors |url=https://www.vcbacked.co/company/pentabind |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated